Skip to main content
OpenTrials
Completed

NCT Number: NCT03851094

Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients

This is a prospective, randomized, open-label study to evaluate effectiveness of applying financial and social incentives via a smartphone-based app in helping participants achieve adherence to PAP therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obstructive Sleep Apnea Apnea Dyssomnias Nervous System Diseases Respiration Disorders Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sleep Data

San Diego, California, 92123, United States

About this study

This is a prospective, randomized, two-arm, open-label study to evaluate effectiveness of applying financial and social incentives via a smartphone-based app in helping participants achieve adherence to therapy. Randomization will include an allocation ratio of 2:1 (control:treatment).

Participants will be recruited based on evidence that they are struggling to achieve adherence to therapy after the first 3 nights of usage. Two 'site to participant' contacts are required during this study. These contacts can either occur at the clinical site or remotely (e.g., by telephone). During the initial contact, their interest in the study and eligibility will be confirmed, then they will be consented, asked to complete the Baseline Questionnaire, and their demographic information will be collected on case report forms (CRFs).

Participants randomized to the intervention (Group B) will be provided with information and assistance in downloading Restful to their smartphone and registering with Wellth.

At the final contact (90 days), the participant will be asked to complete an End of Study Questionnaire and the investigative staff will collect PAP therapy data for the trial period and record it on CRFs. Participants in Group B will have access to the Restful app discontinued. This completes the participant's active participation in the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult participants (≥ 18 years of age)
  • New diagnosis of OSA
  • Prescribed CPAP or APAP for treatment of OSA
  • Prescribed a ResMed flow generator compatible with AirView
  • Owns a smart phone and is willing to download an app on their phone
  • Willing and able to give informed consent
  • Can read and comprehend written and spoken English

Exclusion criteria

  • Have used PAP therapy in the past
  • Have been prescribed bi-level or adaptive servo-ventilation therapy
  • Are participating in another app-based research study
  • Cannot participate for the full duration of the study (at least 90 days)
  • Participants who have a medical history or concurrent illness that the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this study, or constitutes an unacceptable risk to the participant for the duration of the study

Treatment and study plan

Wellth app

Behavioral

The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.

Other names: Restful

Primary outcomes

  1. Mean PAP Usage at 90 Days

    Time frame: 90 days

    Average nightly CPAP use for the 90 day time frame.

Secondary outcomes

  1. % of Participants That Meet Medicare Compliance Standard

    Time frame: 90 days

    Medicare compliance standard is using the PAP therapy for at least 4 hours per day on at least 70% of the days in a consecutive 30-day period any time in the first 90 days of therapy. Those that meet this standard are counted in the results below and divided by all patients.

  2. Change in ESS Questionnaire Scores

    Time frame: 90 days

    Epworth Sleepiness Scale (ESS) will be administered at baseline and 90 days. The unit for this outcome is points. The total score can range from 0 to 24. A larger change or change that decreases from baseline will represent a better outcome. A smaller change or change that increases from baseline will represent a worse outcome. A higher score indicates worse symptoms.

  3. Change in FOSQ-10 Questionnaire Scores

    Time frame: 90 days

    Functional Outcomes of Sleep Questionnaire (FOSQ-10) will be administered at baseline and 90 days. The unit for this outcome is points. The range of scores is 5 to 20. Higher scores indicate better functional status. A larger change or change that decreases from baseline will represent a better outcome. A smaller change or change that increases from baseline will represent a worse outcome.

Sponsors and collaborators

Lead sponsor

ResMed

Industry

Collaborators

  • Wellth Inc.

Registry information

Acronym: Project Dahlia

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Feb 22, 2019
Registry last updated
Jun 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.